Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 349

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 349
---
 three

• The start of a first clinical trial involving a product in the Company's portfolio or the "proof of concept" of a new therapeutic approach involving a product in the Company's portfolio;

• the conclusion of a collaboration or licensing agreement or the receipt of income from collaboration and licensing agreements totalling € 50

• the implementation of six

• obtaining marketing authorization for a product in the Company's portfolio (bonus condition).

The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below:

• Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach;

• Adjustment of the estimation by applying expected turnover rates.

Expenses were € 33 1,226

AGA New-members 2024-1

Expense was € 17

Free performance shares 2024 (AGA Perf Management 2024-1)

These free performance shares granted in 2024 are subject to two

• Selection and presentation to the Supervisory Board of candidates for the position of Chairman of the Executive Board or Chairman of the Board of Directors (depending on the Company's organization) (“ Performance Condition 1”); and/or;

• Recruitment of a new executive for the position of Chairman of the Executive Board or Chairman of the Board of Directors (depending on the Company's organization) (“ Performance Condition 2”).

Expense was € 302

Other free shares

Expenses were € 32

Free performance shares 2024 (AGA Perf Employees 2024-1 / AGA Perf Management 2024-2)

Free performance shares granted in 2024 are subject to the Company's market capitalization and three

• The start of a first clinical trial involving a product in the Company's portfolio or the "proof of concept" of a new therapeutic approach involving a product in the Company's portfolio;

• the conclusion of a collaboration or licensing agreement or the receipt of income from collaboration and licensing agreements totalling € 50

F-66

• a 25

• obtaining marketing authorization for a product in the Company's portfolio (bonus condition).

The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below:

• Estimation of the expectation of gain associated with internal and share price conditions, made on the